title: A critical review on the translational journey of cardioprotective therapies!
abstract: The failure to translate novel cardioprotective therapies tested in pre-clinical studies into the clinical setting for patient benefit can be attributed to a number of factors at different stages of the research process. This review focuses on the evidences and the gaps with regard to the translational journey of cardioprotective interventions. Gaps are classified into 3 main groups: 1) those related to pre-clinical studies, 2) those associated with the validation of infarct size as a good surrogate and 3) those based on design and interpretation of randomized clinical trials on cardioprotection. Addressing these gaps might increase the chances to successfully translate cardioprotective therapies into improving both post-STEMI heart failure and cardiovascular death rates.
authors.affiliation: The Hatter Cardiovascular Institute, University College London, London, United Kingdom.
authors.forename: Xavier
authors.initials: X
authors.lastname: Rossello
authors.affiliation: The Hatter Cardiovascular Institute, University College London, London, United Kingdom; NIHR UCLH Biomedical Research Centre, University College London Hospital & Medical School, London, United Kingdom. Electronic address: d.yellon@ucl.ac.uk.
authors.forename: Derek M
authors.initials: DM
authors.lastname: Yellon
mesh_terms: D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015425:Myocardial Reperfusion / Q000009:adverse effects / Q000379:methods; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D000072657:ST Elevation Myocardial Infarction / Q000150:complications / Q000601:surgery; D055502:Secondary Prevention / Q000379:methods*; D054928:Validation Studies as Topic
keywords: Ischemia–reperfusion injury; Outcomes research; ST-segment elevation myocardial infarction